Abstracts tagged "Major histocompatibility complex (MHC) and psoriatic arthritis"

Abstract Number: 1894 • 2013 ACR/ARHP Annual Meeting
Association Of Alleles and Amino Acids Of The Major Histocompatibility Complex Class I Chain-Related Gene A With Psoriatic Disease
Remy Pollock¹, Fawnda Pellett², Renise Ayearst³, Fatima Abji¹, Dafna D. Gladman² and Vinod Chandran², ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: We previously reported associations between alleles of the major histocompatibility complex class I chain-related gene A (MICA) and psoriatic disease that were independent of…
Abstract Number: 1003 • 2012 ACR/ARHP Annual Meeting
Role of Particular Class I MHC Haplotypes in Determining Different Traits within the Psoriatic Arthritis Phenotypes
Muhammad Haroon¹, Jon T. Giles², Robert Winchester³ and Oliver M. FitzGerald¹, ¹Department of Rheumatology, Dublin Academic Medical Center, St. Vincent's University Hospital, Dublin, Ireland, ²Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ³Dept of Medicine & Pathology, Columbia University, New York, NY
Background/Purpose: A rigorously ascertained psoriatic arthritis (PsA) cohort demonstrated considerable genetic heterogeneity and provided preliminary evidence that MHC genes determine quantitative traits within the PsA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].